Evaluation of the Effect of Inhaled Salbutamol in the Treatment of Neonates with a Diagnosis of TTN

Document Type : Original Article

Authors

1 Student Research Committee, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3 Department of Biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Abstract

Background: Transient tachypnea of the newborn (TTN), the most common cause of transient respiratory distress in neonates, occurs due to insufficient or delayed absorption of fetal alveolar fluid immediately after birth. Given the limited number of studies evaluating the effectiveness of inhaled salbutamol in TTN patients, this study aimed to assess the therapeutic effects of inhaled salbutamol and to investigate its potential side effects.
Methods: This study was a double-blind randomized clinical trial involving 100 infants with a gestational age of at least 35 weeks, who were diagnosed with TTN. The infants were randomly assigned into two groups. Within the first 6 hours after birth, the intervention group received inhaled salbutamol, while the control group received normal saline, both administered nebulization. The effectiveness of salbutamol on clinical and laboratory parameters, as well as its potential side effects, was examined in infants with TTN.                                                                     
Results: The TTN score decreased significantly in the salbutamol group at 1 and 6 hours after the intervention compared with the control group. Additionally, the time required to initiate oral feeding was longer in the group receiving salbutamol. However, regarding the length of hospitalization, duration of oxygen therapy, and other clinical parameters, no significant difference was observed between the two groups.
Conclusion: Since no significant differences were observed in major clinical outcomes between the groups, inhaled salbutamol may be considered a safe and potentially effective therapeutic option for infants with TTN.                                                                                                                                                                  

Keywords

References

1. Daley SF, Nassar GN, Makker K. Transient Tachypnea of the Newborn. StatPearls TI (FL): editor. StatPearls; 2025.
2. Liem JJ, Huq SI, Ekuma O, Becker AB, Kozyrskyj AL. Transient Tachypnea of the Newborn May Be an Early Clinical Manifestation of Wheezing Symptoms. J Pediatr 2007; 151(1): 29–33.
3. Kim MJ, Yoo JH, Jung JA, Byun SY. The effects of inhaled albuterol in transient tachypnea of the newborn. Allergy Asthma Immunol Res 2013; 6(2): 126-30.
4. Liu J, Wang Y, Fu W, Yang CS, Huang JJ. Diagnosis of neonatal transient tachypnea and its differentiation from respiratory distress syndrome using lung ultrasound. Medicine (Baltimore) 2014; 93(27): e197.
5. Mohammadzadeh I, Akbarian-Rad Z, Heidari F, Zahedpasha Y, Haghshenas-Mojaveri M, Mohammadzadeh I, et al. The effect of inhaled salbutamol in transient of tachypnea of the newborn: a randomized clinical trial. Iran J Pediatr 2017; 27(5): e58288.
6. Aslan MT, Güney Varal İ, Tunç G, Bağcı O, Ören A. Systemic inflammatory indices in transient tachypnea of the newborn: a retrospective case–control study. Children (Basel) 2025; 12(6): 727.
7. Malakian A, Dehdashtian M, Aramesh MR, Aletayeb MH, Heidari S. The effect of inhaled salbutamol on the outcomes of transient tachypnea of the newborn. J Chinese Med Assoc 2018; 81(11): 990–7.
8. Maneenil G, Janjindamai W, Dissaneevate S, Thatrimontrichai A. Risk factors of transient tachypnea of the newborn developing into pulmonary hypertension of the newborn: a case-control study. Asian Biomed (Res Rev News) 2023; 16(6): 310-15.
9. Moresco L, Calevo MG, Bruschettini M. Antibiotics for the management of transient tachypnea of the newborn. Cochrane Database Syst Rev 2017; 2017(11): CD012872.
10. Taenaka H, Matthay MA. Mechanisms of impaired alveolar fluid clearance. Anat Rec (Hoboken) 2025; 308(4): 1026–39.
11. Zhou W, Hou Y, Yu T, Wang T, Ding Y, Nie H. Submersion and hypoxia inhibit alveolar epithelial Na+ transport through ERK/NF-κB signaling pathway. Respir Res 2023; 24(1): 117.
12. Aiswarya A, Karthikeyan K. Fluid Restriction in Transient Tachypnea of the Newborn: A Systematic Review of Recent Evidence and Clinical Outcomes. J Comput Anal Appl 2025; 34(7): 78–92.
13. Keleş E, Gebeşçe A, Demirdöven M, Yazgan H, Baştürk B, Tonbul A. The effects of inhaled β-adrenergic agonists in transient tachypnea of the newborn. Glob Pediatr Heal 2016; 3: 2333794X16645258.
14. Talaat AA, Abohashish MMA, Farid TM, Salah MM. Evaluation of inhaled beta-2 agonist in management of transient tachypnea of the newborn. Bull Natl Res Cent 2020; 44(1): 1–5.
15. Madajczak D, Daboval T, Lauterbach R, Łoniewska B, Błaż W, Szczapa T, et al. Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial). Front Pediatr 2023; 10: 1060843.
16. Licker M, Tschopp JM, Robert J, Frey JG, Diaper J, Ellenberger C. Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection. Chest 2008; 133(4): 845–52.
17. Rabea Bakry A, Abd El latif Atia A, Refaat Hablas H, Fathy Abd El Aziz A, Ashraf Rabea Bakry B. The role of inhaled β2-adrenergic agonists in treatment of transient tachypnea of the newborn. Al-Azhar J Ped 2019; 22(1): 37–52.
18. Neri C, Sartorius V, De Luca D. Transient tachypnoea: new concepts on the commonest neonatal respiratory disorder. Eur Respir Rev 2025; 34(175): 240112.
19. Demirtas MS, Erdal H, Kilicbay F, Tunc G. Association between thiol-disulfide hemostasis and transient tachypnea of the newborn in late-preterm and term infants. BMC Pediatr 2023; 23(1): 135.
20. Alhassen Z, Vali P, Guglani L, Lakshminrusimha S, Ryan RM. Recent advances in pathophysiology and management of transient tachypnea of newborn. J Perinatol 2020; 41(1): 6-16.
21. Babaei H, Dabiri S, Mohammadi Pirkashani L, Mohsenpour H. Effects of Salbutamol on the Treatment of Transient Tachypnea of the Newborn. Iranian Journal of Neonatology. 2019: 10(1): 42-9.
22. Mussavi M, Asadollahi K, Kayvan M, Sadeghvand S. Effects of nebulized albuterol in transient tachypnea of the newborn a clinical trial. Iran J Pediatr 2017; 27(3).
World Journal of Peri & Neonatology
Volume 7, Issue 2
October 2025
Pages 64-71

Files

History

  • Receive Date: 31 December 2025
  • Accept Date: 31 December 2025

Share

How to cite

Statistics